QIAGEN N.V. (QGEN) Stock Price

QGENStock

$46.13−4.16%52W

Market Cap$9.53B

P/E22.37x

PEG Ratio1.23

Div yield0.62%

Beta0.59

QGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)0.56%

Price vs S&P 500 (4W)4.34%

PEG Ratio1.23

VGM Score57.58

P/E Ratio (Annual)22.37x

Indicated Dividend Yield (Annual)0.62%

P/CF (Annual)14.53x

Book Value / Share (Quarterly)$16.26

P/TBV (Annual)2.88x

Indicated Dividend (Annual)$0.35

Revenue Growth (3Y)-0.81%

Cash Flow / Share (Quarterly)$2.13

Price vs S&P 500 (YTD)-9.35%

Gross Margin (TTM)62.45%

Net Profit Margin (TTM)19.49%

EPS (TTM)$1.94

10-Day Avg Trading Volume1.89M

EPS Excl Extra (TTM)$1.94

Revenue Growth (5Y)2.25%

EPS (Annual)$1.94

Dividend / Share (Annual)$0.25

ROI (Annual)7.82%

Gross Margin (Annual)63.67%

Net Profit Margin (5Y Avg)16.89%

Cash / Share (Quarterly)$3.84

P/E Basic Excl Extra (TTM)23.22x

Revenue Growth QoQ (YoY)0.28%

EPS Growth (5Y)4.22%

P/E Normalized (Annual)22.37x

ROA (Last FY)6.76%

Revenue Growth TTM (YoY)2.96%

EBITD / Share (TTM)$2.16

ROE (5Y Avg)10.26%

Operating Margin (TTM)21.21%

Cash Flow / Share (Annual)$2.06

P/B Ratio2.83x

P/B Ratio (Quarterly)2.40x

Net Income / Employee (Annual)$75,100

EV / Revenue (TTM)4.94x

Net Interest Coverage (TTM)27.84x

ROA (TTM)6.68%

EPS Growth QoQ (YoY)12.58%

EV / EBITDA (TTM)22.84x

EPS Incl Extra (Annual)$1.94

Current Ratio (Annual)3.90x

Quick Ratio (Quarterly)2.06x

3-Month Avg Trading Volume2.63M

52-Week Price Return-4.16%

EV / Free Cash Flow (Annual)23.21x

P/E Incl Extra (TTM)23.22x

Revenue / Employee (TTM)$371,500

Tangible BV / Share (Quarterly)$14.55

P/S Ratio (Annual)4.55x

Asset Turnover (Annual)0.33x

52-Week High$57.81

Operating Margin (5Y Avg)20.11%

EPS Excl Extra (Annual)$1.94

CapEx CAGR (5Y)-7.40%

Tangible BV CAGR (5Y)10.36%

26-Week Price Return10.46%

Quick Ratio (Annual)3.21x

13-Week Price Return12.10%

Total Debt / Equity (Annual)0.44x

Current Ratio (Quarterly)2.85x

Enterprise Value$10.38B

Revenue / Share Growth (5Y)3.04%

Asset Turnover (TTM)0.34x

Book Value / Share Growth (5Y)6.64%

Revenue / Employee (Annual)$369,600

Inventory Turnover (Annual)2.61x

Pretax Margin (Annual)23.46%

Cash / Share (Annual)$5.07

3-Month Return Std Dev32.38%

Gross Margin (5Y Avg)63.87%

Net Income / Employee (TTM)$72,400

EBITDA CAGR (5Y)2.97%

EBITDA Interim CAGR (5Y)-4.16%

ROE (Last FY)11.25%

Net Interest Coverage (Annual)507.15x

EPS Basic Excl Extra (Annual)$1.94

P/FCF (TTM)21.58x

Receivables Turnover (TTM)5.28x

EV / Free Cash Flow (TTM)23.56x

Total Debt / Equity (Quarterly)0.49x

EPS Incl Extra (TTM)$1.94

Receivables Turnover (Annual)5.38x

ROI (TTM)7.73%

P/S Ratio (TTM)4.53x

Pretax Margin (5Y Avg)20.64%

Revenue / Share (Annual)$9.56

Tangible BV / Share (Annual)$15.66

Forward P/E16.86x

Free OCF CAGR (5Y)23.83%

Price vs S&P 500 (52W)-19.69%

P/E Ratio (TTM)23.22x

EPS Growth TTM (YoY)13.03%

Year-to-Date Return2.58%

5-Day Price Return1.81%

EPS Normalized (Annual)$1.94

ROA (5Y Avg)5.78%

Net Profit Margin (Annual)20.33%

Month-to-Date Return5.42%

Cash Flow / Share (TTM)$2.35

EBITD / Share (Annual)$2.16

EPS Growth (3Y)0.85%

Operating Margin (Annual)22.17%

LT Debt / Equity (Annual)0.44x

P/CF (TTM)14.53x

ROI (5Y Avg)6.81%

P/E Excl Extra (TTM)23.22x

LT Debt / Equity (Quarterly)0.48x

EPS Basic Excl Extra (TTM)$1.94

P/TBV (Quarterly)2.68x

Payout Ratio (Annual)12.77%

P/B Ratio (Annual)2.58x

Inventory Turnover (TTM)2.61x

Pretax Margin (TTM)21.99%

Book Value / Share (Annual)$17.45

Price vs S&P 500 (13W)9.42%

Net Margin Growth (5Y)1.15%

Beta0.59x

P/FCF (Annual)21.26x

Revenue / Share (TTM)$10.11

ROE (TTM)11.60%

52-Week Low$32.53

vGradeC

gGradeC

mGradeB

vgmGradeC

QGEN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.60	$0.62	+3.45%(+$0.02)
Q1 2026	May 6, 2026	$0.54	$0.54	+0.00%(+$0.00)
Q4 2025	Feb 4, 2026	$0.62	$0.62	+0.13%(+$0.00)
Q3 2025	Nov 4, 2025	$0.62	$0.64	+4.07%(+$0.03)
Q2 2025	Aug 5, 2025	$0.63	$0.63	-0.46%(-$0.00)

QGEN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.65

3.73

3.77

3.70

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About QIAGEN N.V.

Qiagen develops proprietary sample preparation and diagnostic solutions serving life sciences research and molecular diagnostics equally. The business model generates roughly 90% of revenue from consumables, with the remainder from instruments and services. North America represents the largest market (52% of 2024 sales), followed by EMEA (33%) and Asia-Pacific (15%).